cas 37949-03-4|| where to buy 5,6,8,9-Tetrahydrobenzocyclohepten-7-one

Nom du produit:5,6,8,9-Tetrahydrobenzocyclohepten-7-one

IUPAC Name:6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-one

Unité d'emballage	Stock disponible	Prix($)
CM153084-10g	in stock	ŵŵǜȺ
CM153084-25g	in stock	ŵƦȺƎ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 37949-03-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:37949-03-4; Formule moléculaire:C11H12O; Point de fusion:-; Code SMILES:O=C1CCC2=CC=CC=C2CC1; Densité:

: Numéro de catalogue:CM153084; Poids moléculaire:160.22; Point d'ébullition:288.2±29.0°C at 760 mmHg; N° Mdl:MFCD09867716; Stockage:Store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Bemcentinib; Bemcentinib is a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. Extensive studies confirm the ability to combine bemcentinib with immune checkpoint inhibitors, chemotherapies and targeted therapies with the goal of improving a patient’s immune response and delaying the development of chemoresistance. Bemcentinib is currently being investigated in combination with immune checkpoint inhibition and chemotherapy in first line NSCLC patients harboring mutations in the STK11 gene, a known prognostic factor of poor response to existing therapies.